<DOC>
	<DOCNO>NCT01799902</DOCNO>
	<brief_summary>This study non interventional study investigational medicine provide . Procedures examination follow institution standard care practice . The therapeutic approach decide advance protocol influence way protocol . After standard evaluation investigator decide treatment strategy upon eligibility criterion meet propose subject participate study . Informed consent collect subject . The study consist 3 possible observational visit ; V1 ( enrolment ) , V2 V3 ( follow ) . During observational visit ( V1 , V2 V3 ) patient complete I-PSS ( International Prostate Symptom Score ) questionnaire include Quality Of Life ( QOL ) questionnaire Patient assessment treatment benefit satisfaction use Visual Analogue Scale ( VAS ) . The patient ask complete void diary first 3 day Visit 1 ( Baseline diary ) , 3 day Visit 2 3 day Visit 3 . Prostate Specific Antigen ( PSA ) measurement- Uroflowmetry - Post Voiding Residual volume Trans Rectal Ultra Sound data collect available . During observational visit ( V1 , V2 V3 ) investigator complete assessment treatment benefit satisfaction use VAS .</brief_summary>
	<brief_title>Treatment Symptoms Male Patients With Lower Urinary Tract Symptoms ( LUTS ) Predominant Storage Symptoms ( Overactive Bladder Syndrome )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>The following subject include study answer follow criterion : prescribe solifenacin 510mg accord Summary Product Characteristics ( SmPC ) . Subjects diagnose Lower Urinary Tract Symptoms ( LUTS ) substantial storage disorder define urgency , and/or frequency and/or Urge Urinary Incontinence ( UUI ) discretion investigator . IPSS storage subscore &gt; 8 Subject expect require least 3 month treatment solifenacin . Any reason follow current medical knowledge , physical condition patient opinion investigator contraindicate administration solifenacin subject , sign symptom suggestive urinary tract infection ( confirm positive urine analysis ) . History bladder obstruction adequately correct . Anticipate plan participate another study study period 12 week study entry .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Observational</keyword>
	<keyword>Non-Interventional Prospective</keyword>
	<keyword>Phase IV Treatment</keyword>
	<keyword>Overactive Bladder Syndrome</keyword>
	<keyword>Solifenacin</keyword>
</DOC>